View Archive »
About The Cover
A combination of rapamycin and metformin prevents mitotic arrest in WI-38t cells. After 24 hours, cells were microphotographed, collected and flow cytometry was performed. See Apontes et al.
|
|
Table of Contents
|
| Chaperones and the maturation of steroid hormone receptor complexes |
|
https://doi.org/10.18632/oncotarget.238
|
| 104-106 |
|
| Novel strategies of protecting noncancer cells during chemotherapy: Are they ready for clinical testing |
|
https://doi.org/10.18632/oncotarget.249
|
| 107-108 |
|
| Exploiting p53 Status to Enhance Effectiveness of Chemotherapy by Lowering Associated Toxicity |
|
https://doi.org/10.18632/oncotarget.247
|
| 109-112 |
Reviews
|
| The Challenge for Gene Therapy: Innate Immune Response to Adenoviruses |
|
https://doi.org/10.18632/oncotarget.231
|
| 113-121 |
|
| Recent Advances in AntiAngiogenic Therapy of Cancer |
|
https://doi.org/10.18632/oncotarget.234
|
| 122-134 |
|
| Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health |
|
https://doi.org/10.18632/oncotarget.240
|
| 135-164 |
|
| Personalizing Therapy with Targeted Agents in NonSmall Cell Lung Cancer |
|
https://doi.org/10.18632/oncotarget.245
|
| 165-177 |
Research Papers
|
| IgH gene rearrangements as plasma biomarkers in NonHodgkin's Lymphoma patients |
|
https://doi.org/10.18632/oncotarget.235
|
| 178-185 |
|
| Inhibition of SREBP1 sensitizes cells to death ligands |
|
https://doi.org/10.18632/oncotarget.239
|
| 186-196 |
|
| APC +/ alters colonic fibroblast proteome in FAP |
|
https://doi.org/10.18632/oncotarget.241
|
| 197-208 |
|
| Proteotoxic stress targeted therapy PSTT: induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib |
|
https://doi.org/10.18632/oncotarget.246
|
| 209-221 |
|
| Exploring longterm protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture |
|
https://doi.org/10.18632/oncotarget.248
|
| 222-233 |
Research Perspectives
|
| The RPMdm2p53 Pathway and Tumorigenesis |
|
https://doi.org/10.18632/oncotarget.228
|
| 234-238 |
|
| Mcl1 Ubiquitination and Destruction |
|
https://doi.org/10.18632/oncotarget.242
|
| 239-244 |
|
| Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders |
|
https://doi.org/10.18632/oncotarget.233
|
| 245-250 |
|
| MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk |
|
https://doi.org/10.18632/oncotarget.243
|
| 251-258 |
|
| A microRNAdependent circuit controlling p63/p73 homeostasis: p53 family crosstalk meets therapeutic opportunity |
|
https://doi.org/10.18632/oncotarget.244
|
| 259-264 |
|
| miRNA signature of schwannomas: Possible roles of “tumor suppressor†miRNAs in benign tumors |
|
https://doi.org/10.18632/oncotarget.251
|
| 265-270 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC
